Comparison of the efficacy and safety of irbesartan and olmesartan in patients with hypertension (EARTH study).

Abstract

Fifty-four patients were randomly divided into irbesartan and olmesartan groups. Blood pressure (BP) was significantly decreased in all patients at 12 weeks. In particular, BP in patients who initially received irbesartan showed significant reductions. The equality of variance of BP in the irbesartan group was significantly smaller than that in the olmesartan group at 12 weeks. Blood concentrations of adiponectin were significantly increased in the irbesartan group at 12 weeks. Log [pentraxin-3] in the irbesartan group were significantly decreased. In conclusion, the ability of irbesartan to reduce BP is comparable to that of olmesartan with equivalent safety.

• Authors: Joji Morii, Shin-ichiro Miura, Yuhei Shiga, Makoto Sugihara, Tadaaki Arimura, Hideto Sako, Bo Zhang, Yoshinari Uehara, Keijiro Saku
• Journal: Clinical and experimental hypertension (New York, N.Y. : 1993) (Clin Exp Hypertens) Vol. 34 Issue 5 Pg. 342-9 ( 2012) ISSN: 1525-6006 [Electronic] England
• PMID: 22568596 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Angiotensin II Type 1 Receptor Blockers
• Antihypertensive Agents
• Biphenyl Compounds
• Imidazoles
• Tetrazoles
• olmesartan
• Irbesartan

Topics

• Aged
• Aged, 80 and over
• Angiotensin II Type 1 Receptor Blockers (adverse effects, therapeutic use)
• Antihypertensive Agents (adverse effects, therapeutic use)
• Biphenyl Compounds (adverse effects, therapeutic use)
• Blood Pressure (drug effects)
• Female
• Humans
• Hypertension (drug therapy)
• Imidazoles (adverse effects, therapeutic use)
• Irbesartan
• Male
• Middle Aged
• Tetrazoles (adverse effects, therapeutic use)